Skip to main content
. 2012 Nov 1;3(6):406–410. doi: 10.6004/jadpro.2012.3.6.8

Figure 1.

Figure 1

Figure 1. 68-year-old male with myeloma receiving weekly subcutaneous injections of bortezomib together with daily thalidomide and weekly dexamethasone. A. Two weeks after injection of bortezomib: Fading of hyperpigmented macular skin discoloration without pain or pruritus. B. One and three weeks after injection of bortezomib: Hyperpigmented macular skin discoloration without pain or pruritus. Near-complete resolution at 3 weeks.